Dimebon Dimebolin Information Availability » Product Candidates http://dimebonalzheimers.com Dimebolin Latrepirdine Available Online Pharmacy Internet ? Fri, 10 Feb 2012 06:19:47 +0000 en hourly 1 http://wordpress.org/?v=3.2.1 Morgan Joseph Analysts Initiate Coverage on Medivation Inc (MDVN) http://dimebonalzheimers.com/973/morgan-joseph-analysts-initiate/ http://dimebonalzheimers.com/973/morgan-joseph-analysts-initiate/#comments Sat, 24 Sep 2011 04:08:06 +0000 admin http://dimebonalzheimers.com/?p=973
Analysts at Morgan Joseph initiated coverage on shares of Medivation Inc (NASDAQ: MDVN) in a research note on Wednesday. The analysts set a “buy” rating and a $30.00 price target on the stock. Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company’s [...]



]]>

Analysts at Morgan Joseph initiated coverage on shares of Medivation Inc (NASDAQ: MDVN) in a research note on Wednesday. The analysts set a “buy” rating and a $30.00 price target on the stock.

Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company’s product candidates in clinical development are dimebon (latrepirdine), which is in Phase III development for the treatment of Alzheimer’s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer. Its dimebon program is partnered with Pfizer Inc. (Pfizer) and its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas).Shares of Medivation Inc opened at 18.74 on Thursday. Medivation Inc has a 52 week low of $9.86 and a 52 week high of $25.50. The stock’s 50-day moving average is $17.97 and its 200-day moving average is $19.98. The company has a market cap of $654.2 million.

http://www.newsystocks.com/News/4107368/morgan-joseph-analysts-initiate-coverage-on-medivation-inc-mdvn

 

Winnipeg Alternative Therapy

Dimebon Dimebolin Information Availability

]]> http://dimebonalzheimers.com/973/morgan-joseph-analysts-initiate/feed/ 0 Medivation Inc (NASDAQ: MDVN) Closes Above 50-Day Moving Average, Hits $16.07 http://dimebonalzheimers.com/702/medivation-nasdaq-mdvn-closes-50day-moving-average-hits-1607/ http://dimebonalzheimers.com/702/medivation-nasdaq-mdvn-closes-50day-moving-average-hits-1607/#comments Thu, 06 Jan 2011 06:20:01 +0000 admin http://www.dimebonalzheimers.com/?p=702
Shares of Medivation Inc (NASDAQ: MDVN) closed above its 50-day moving average on Monday. The stock has a 50-day moving average of $12.50 and last traded at $16.07. Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company’s product candidates in clinical development [...]



]]>

Shares of Medivation Inc (NASDAQ: MDVN) closed above its 50-day moving average on Monday. The stock has a 50-day moving average of $12.50 and last traded at $16.07.

Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company’s product candidates in clinical development are dimebon (latrepirdine), which is in Phase III development for the treatment of Alzheimer’ s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer. Its dimebon program is partnered with Pfizer Inc. (Pfizer) and its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas).

Medivation Inc (NASDAQ: MDVN) traded up 6.26% during mid-day trading on Monday. The stock has a 52 week low of $8.43 and a 52 week high of $40.49. The company has a market cap of $557.3 million and a price-to-earnings ratio of N/A.

http://www.americanbankingnews.com/2011/01/03/medivation-inc-nasdaq-mdvn-closes-above-50-day-moving-average-hits-16-07/

Dimebon

http://www.dimebonalzheimers.com/

Extended Stay Hotel Winnipeg

Winnipeg Alternative Therapies

]]> http://dimebonalzheimers.com/702/medivation-nasdaq-mdvn-closes-50day-moving-average-hits-1607/feed/ 0 Calls Purchased on Medivation (MDVN) http://dimebonalzheimers.com/666/calls-purchased-medivation-mdvn/ http://dimebonalzheimers.com/666/calls-purchased-medivation-mdvn/#comments Sat, 04 Dec 2010 14:49:28 +0000 admin http://www.dimebonalzheimers.com/?p=666
Shares of Medivation (NASDAQ: MDVN) are higher on the session by 0.45%, currently trading at $11.27. The stock has been moving largely higher over the past three months, though it is currently trading below the 50-day and 200-day moving averages. Options traders are buying calls on the name today. Though action has been primarily in [...]



]]>

Shares of Medivation (NASDAQ: MDVN) are higher on the session by 0.45%, currently trading at $11.27. The stock has been moving largely higher over the past three months, though it is currently trading below the 50-day and 200-day moving averages.

Options traders are buying calls on the name today. Though action has been primarily in small lots, overall call volume is now running at 9.94x the daily average with 75% of all calls traded being purchases on the offer.

Traders are buying the $10.00, $12.50, and $14.00 strikes in multiple months.

Medivation, Inc. is a biopharmaceutical company. The company focuses on the development of small molecule drugs to treat serious diseases. The company’s product candidates in clinical development are dimebon, which is in Phase III development for the treatment of Alzheimer’s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer.

http://www.benzinga.com/trading-ideas/long-ideas/10/11/633902/calls-purchased-on-medivation-mdvn

Dimebon

http://www.dimebonalzheimers.com/

Mazda 3 Edmonton

Winnipeg Manitoba Extended Stay Mainstay Hotels

]]> http://dimebonalzheimers.com/666/calls-purchased-medivation-mdvn/feed/ 0